Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.
Official title: A Phase Ib Study Evaluating the Safety and Efficacy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-03
Completion Date
2027-12
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
ZG006
ZG006 will be administered as an IV infusion.
Serplulimab
Serplulimab will be administered as an IV infusion.
Locations (1)
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China